Hoping that researchers would replace them with technologies that more accurately reflect human biology, the US Food and Drug Administration (FDA) recently introduced a plan to phase out animal testing during the preclinical development of monoclonal antibodies and other drugs.1
A few weeks later, the National Institutes of Health (NIH) followed with the announcement of a new initiative to develop non-animal models for biomedical research.2
The FDA emphasised that the use of advanced technologies — such as organoids made from human cells and computational models that simulate biological processes — could accelerate drug development and improve safety while lowering research costs, potentially bringing down drug prices.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
